BR9913951A - Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir - Google Patents

Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir

Info

Publication number
BR9913951A
BR9913951A BR9913951-0A BR9913951A BR9913951A BR 9913951 A BR9913951 A BR 9913951A BR 9913951 A BR9913951 A BR 9913951A BR 9913951 A BR9913951 A BR 9913951A
Authority
BR
Brazil
Prior art keywords
lamivudine
hepatitis
infection
treatment
flamciclovir
Prior art date
Application number
BR9913951-0A
Other languages
English (en)
Inventor
Ying-Kit Leung
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of BR9913951A publication Critical patent/BR9913951A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Resumo da Patente de Invenção para: <B>''TRATAMENTO DE INFECçãO DE HEPATITE B COM TIMOSINA ALFA 1 EM COMBINAçãO COM LAMIVUDINA OU EM COMBINAçãO COM LAMIVUDINA E FAMCICLOVIR''<D> Tratamento de infecção por vírus da hepatite B, em um paciente, por administração, ao paciente, de um regime de droga incluindo uma quantidade eficaz anti-viral de timosina alfa 1 (T<244>1), uma quantidade eficaz anti-viral de lamivudina e, opcionalmente, uma quantidade eficaz anti-viral de famciclovir.
BR9913951-0A 1998-09-25 1999-09-22 Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir BR9913951A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10177198P 1998-09-25 1998-09-25
US09/168,869 US6288033B1 (en) 1998-09-25 1998-10-09 Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir
PCT/US1999/021954 WO2000018417A2 (en) 1998-09-25 1999-09-22 Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine

Publications (1)

Publication Number Publication Date
BR9913951A true BR9913951A (pt) 2001-06-12

Family

ID=26798617

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913951-0A BR9913951A (pt) 1998-09-25 1999-09-22 Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir

Country Status (16)

Country Link
US (1) US6288033B1 (pt)
EP (1) EP1115420B1 (pt)
JP (1) JP2002525333A (pt)
CN (1) CN1183964C (pt)
AT (1) ATE220332T1 (pt)
AU (1) AU757833B2 (pt)
BR (1) BR9913951A (pt)
CA (1) CA2345462A1 (pt)
DE (1) DE69902103T2 (pt)
DK (1) DK1115420T3 (pt)
ES (1) ES2181502T3 (pt)
HK (1) HK1041215B (pt)
MX (1) MXPA01003105A (pt)
PT (1) PT1115420E (pt)
TR (1) TR200100845T2 (pt)
WO (1) WO2000018417A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003039582A (ja) * 2001-07-19 2003-02-13 Three M Innovative Properties Co 湿潤防滑性シート及び湿潤防滑構造体
US6855346B2 (en) * 2001-10-05 2005-02-15 Tzu-Sheng Wu Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
PL370453A1 (en) * 2001-10-26 2005-05-30 Rhode Island Hospital Thymosin augmentation of genetic immunization
US20060259603A1 (en) * 2005-05-16 2006-11-16 Shrader Anthony G User based - workflow and business process management
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
MX2008013872A (es) * 2006-05-02 2008-11-14 Sigma Tau Ind Farmaceuti Uso de timosina alfa 1, sola o en combinacion con ptx3 o ganciclovir, para el tratamiento de infeccion por citomegalovirus.
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US8716012B2 (en) * 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
CA2826875A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
JP2016507569A (ja) * 2013-02-07 2016-03-10 トビラ セラピューティクス， インコーポレイテッド ラミブジン結晶塩
US11136378B2 (en) * 2015-11-30 2021-10-05 HBVtech LLC Methods of curing HBV infection and providing complete protection against HBV infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904855D0 (en) 1989-03-03 1989-04-12 Beecham Group Plc Pharmaceutical treatment
US5308833A (en) 1992-02-06 1994-05-03 Sciclone Pharmaceuticals Method for treating hepatitis B carriers with minimal disease
EP0627930A4 (en) 1992-07-13 1997-08-20 Kenneth E Sherman COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir

Also Published As

Publication number Publication date
AU6057099A (en) 2000-04-17
US6288033B1 (en) 2001-09-11
TR200100845T2 (tr) 2001-10-22
HK1041215B (zh) 2005-08-26
DE69902103T2 (de) 2003-02-27
CN1183964C (zh) 2005-01-12
CA2345462A1 (en) 2000-04-06
EP1115420B1 (en) 2002-07-10
JP2002525333A (ja) 2002-08-13
ATE220332T1 (de) 2002-07-15
MXPA01003105A (es) 2003-05-15
EP1115420A2 (en) 2001-07-18
ES2181502T3 (es) 2003-02-16
PT1115420E (pt) 2002-11-29
DE69902103D1 (de) 2002-08-14
DK1115420T3 (da) 2002-11-04
WO2000018417A3 (en) 2000-07-06
WO2000018417A2 (en) 2000-04-06
HK1041215A1 (en) 2002-07-05
CN1320041A (zh) 2001-10-31
AU757833B2 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
PT956861E (pt) Terapia combinada compreendendo ribavirina e interferao alfa em doentes sem tratamento antiviral anterior tendo infeccao cronica pelo virus da hepatite c
MY133891A (en) Polyethylene glycol modified interferon therapy
MY141594A (en) 3&#39;-PRODRUGS OF 2&#39;-DEOXY-ß-L-NUCLEOSIDES
DE60131250T8 (de) Nucleosid-analoga mit monozyklischen basischen carboxamidingruppen
TR200402565T4 (tr) Hepatit delta virüsü enfeksiyonunun tedavi edilmesinde ß-L-2&#39;-deoksi-nükleosidlerin kullanımı
RS20120201A3 (en) METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C
DK0831852T3 (da) Nukleosider med anti-hepatitis B-virusaktivitet
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
BR9913951A (pt) Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir
TR200101085T2 (tr) Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA&#39;nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
ATE339211T1 (de) L-fmau zur behandlung von hepatitis-delta-virus- infizierung
MD990258A (en) Method of treatment of the acute viral hepatitis B
FI954127A0 (fi) Menetelmä C-hepatiitin hoitamiseksi interferonihoitoon reagoimattomissa potilaissa
ATE348628T1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
MXPA94003453A (es) Metodo y composicion para el tratamiento de pacientes con hepatitis b que tienen descompensacion hepatica.
RU98109203A (ru) Способ лечения вирусного гепатита b у детей
ATE332704T1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 10 (VIII) DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.